Patent cliff contd. - A dozen blockbuster drugs about to get generic rivals - Yahoo! Finance

These are blockbuster drugs, with more than $1 billion in annual global sales,
set to go off patent and get generic competition in the U.S. in the next two
years:

Oct. 2011 Zyprexa olanzapine schizophrenia/bipolar Eli
Lilly
Nov. 2011 Lipitor atorvastatin high cholesterol Pfizer
March 2012 Lexapro escitalopram depression Forest
Labs
March 2012 Seroquel quetiapine schizophrenia/bipolar
AstraZeneca
March 2012 Avapro/Avalide irbesartan high blood pressure
Bristol-Myers/Sanofi
April 2012 Provigil modafinil narcolepsy Cephalon
May 2012 Plavix clopidogrel clot prevention
Bristol-Myers/Sanofi
July 2012 Tricor fenofibrate high triglycerides Abbott
Aug. 2012 Singulair montelukast asthma/allergies Merck
Aug. 2012 Actos pioglitazone diabetes Takeda
Sept. 2012 Diovan valsartan high blood pressure Novartis
Sept. 2012 Geodon ziprasidone bipolar disorder Pfizer
Nov. 2012 Lidoderm lidocaine pain patch Endo
Dec. 2012 Atacand candesartan heart failure
AstraZeneca
March 2013 Lovaza omega-3-acid high triglycerides
GlaxoSmithKline
Aug. 2013 Temodar temozolomide brain tumors Merck
------
Note: Patent expiration/generic arrival dates can change due to litigation or
regulatory issues.
Sources: Medco Health Solutions Inc., company Web sites.

via finance.yahoo.com

Posted via email from Jack's posterous